60 Degrees Pharmaceuticals Enters Exclusive Option Agreement With Florida State's Research Foundation Regarding IP To Develop Castanospermine For Multiple Tick-Borne Diseases

60 Degrees Pharmaceuticals, Inc.

SXTP

0.00

License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease
Agreement builds on Company's expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis
Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.